Evidence map›Paper›PMID 41160709›Full record

ArticleCardiovascular research2025

Age-dependent remodelling of arterial chemoafferent innervation in hypertension.

Audrys G Pauza, Igor Felippe, Iris de Laat, Olivia Gold, Xin Shen, Julian F R Paton

Abstract read
In one paragraph

Article in Cardiovascular research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Audrys G PauzaManaaki Mānawa-The Centre for Heart Research, Department of Physiology, Faculty of Medical & Health Sciences, University of Auckland, 85 Park Road, Grafton, Auckland 1023, New Zealand.ORCID 0000-0001-9635-8872
Igor FelippeManaaki Mānawa-The Centre for Heart Research, Department of Physiology, Faculty of Medical & Health Sciences, University of Auckland, 85 Park Road, Grafton, Auckland 1023, New Zealand.ORCID 0000-0002-8582-2104
Iris de LaatManaaki Mānawa-The Centre for Heart Research, Department of Physiology, Faculty of Medical & Health Sciences, University of Auckland, 85 Park Road, Grafton, Auckland 1023, New Zealand.
Olivia GoldManaaki Mānawa-The Centre for Heart Research, Department of Physiology, Faculty of Medical & Health Sciences, University of Auckland, 85 Park Road, Grafton, Auckland 1023, New Zealand.
Xin ShenManaaki Mānawa-The Centre for Heart Research, Department of Physiology, Faculty of Medical & Health Sciences, University of Auckland, 85 Park Road, Grafton, Auckland 1023, New Zealand.ORCID 0000-0003-4429-8358
Julian F R PatonManaaki Mānawa-The Centre for Heart Research, Department of Physiology, Faculty of Medical & Health Sciences, University of Auckland, 85 Park Road, Grafton, Auckland 1023, New Zealand.

Funding

Ernest Hyam Davis & Ted & Mollie Carr Legacies 2026G.R. Winn Trust 2016G.R. Winn Trust 2025Health Research Council of New ZealandMaurice and Phyllis Paykel TrustNational Heart Foundation of New Zealand 2021Sidney Taylor Trust
6 · The paper itself

Abstract

aimsElevated sympathetic nerve activity (eSNA) is a hallmark of cardiovascular disease and represents an important clinical target for disease management. A known driver of eSNA is aberrant signalling from, and sensitization of, the carotid body (CB) arterial chemoreceptors. Sensitization is coupled with CB hypertrophy, the cause of which remains unclear. Here, we set out to characterize the morphological basis of CB hypertrophy in hypertension to understand its aberrant activity. METHODS AND

resultsUsing high-throughput fluorescence microscopy, we mapped the neurovascular interface and chemoafferent innervation of the CB of spontaneously hypertensive rats (SHR) across multiple age groups. We show that CB hypertrophy driven by chemosensory (type I) cell hyperplasia and an expanded vascular network is evident in 4-6-week-old SHR without established hypertension. Specifically, CB hypertrophy in the SHR is linked to increased chemoafferent innervation and an age-dependent remodelling of nerve fibre composition.

conclusionsCB hypertrophy in hypertension is associated with chemosensory hyperplasia and angiogenesis, likely mediated by impaired HIF-PHD signalling in the SHR. We propose that CB size may serve as a candidate marker of chemoafferent sensitivity and the efficacy of therapies targeting the CB. However, further validation in humans is needed to support this link. Neurotrophic pathways promoting increased chemoafferent innervation in hypertension are proposed as a potential target for modulating CB activity in sympathetically mediated diseases.

Indexed as

AgingArterial PressureCarotid BodyChemoreceptor CellsHypertensionVascular RemodelingAge FactorsAnimalsDisease Models, AnimalHyperplasiaHypertrophyMaleRats, Inbred SHRSignal TransductionArterial chemoreflexCarotid bodyHypertensionInnervationSympathetic activity

Identifiers

PMID41160709
PMCPMC12687876

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.